Key result
Inspiron sirolimus-eluting stent yields ~7% 24-month major cardiovascular events in real-world PCI.
Why the study?
Although the third-generation Inspiron sirolimus-eluting stent is widely used in Brazil, long-term real-world evidence on its safety and effectiveness remains limited.
Does percutaneous coronary intervention with the Inspiron™ biodegradable polymer sirolimus-eluting stent provide safe and effective 24-month clinical outcomes (MACE) in an unselected real-world population with native coronary artery disease?
Cohort (n=2,803)
Yes
Does percutaneous coronary intervention with the Inspiron™ biodegradable polymer sirolimus-eluting stent provide safe and effective 24-month clinical outcomes (MACE) in an unselected real-world population with native coronary artery disease?
In a large real-world Brazilian registry of 2,803 patients, the thin-strut biodegradable-polymer Inspiron™ sirolimus-eluting stent demonstrated low 24-month rates of MACE (6.7%), target lesion revascularization (0.9%), and stent thrombosis (0.6%) despite a high prevalence of acute coronary syndromes and complex lesions.
Answers are grounded in this paper and cite their sources.
Supports Inspiron stent in unselected real-world PCI; extends observational data but leaves randomized confirmation open.
Background The Inspiron™ sirolimus-eluting stent (SES) is a third-generation coronary stent featuring thin struts and an abluminal biodegradable polymer coating. Although it is widely used in Brazil, long-term real-world evidence remains limited. Objectives To evaluate the safety and effectiveness of the Inspiron™ SES over 24 months in an unselected population undergoing percutaneous coronary intervention (PCI). Methods This pooled analysis included 2,803 consecutive patients who underwent Inspiron™ SES implantation between June 2017 and January 2022 at 25 Brazilian centers. The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, MI, and target lesion revascularization (TLR) at 24 months. Kaplan-Meier survival analysis, Cox proportional hazards regression, and restricted cubic spline models were used. A two-sided p-value < 0.05 was considered statistically significant. Results At 24 months, the cumulative incidence of MACE was 6.7%, with rates of 5.4% for all-cause mortality, 2.3% for cardiovascular mortality, 1.2% for MI, 0.9% for TLR, and 0.6% for definite or probable stent thrombosis (ST). Patients with a vessel diameter < 2.5 mm had significantly higher rates of MACE, cardiovascular death, repeat revascularization, and ST (p = 0.022). Independent predictors of MACE included older age (p = 0.034), left main or three-vessel coronary artery disease (p = 0.024), and acute coronary syndrome as the indication for PCI (p < 0.001). Conclusions In this large real-world registry, the Inspiron™ SES demonstrated favorable safety and effectiveness through 24 months, with low rates of ST and repeat revascularization despite the inclusion of complex coronary lesions.
No takes yet. Share an insight, caveat, or question.
Soccol et al. (2026) conducted a cohort in Coronary artery disease undergoing percutaneous coronary intervention (PCI) (n=2,803). Inspiron biodegradable polymer sirolimus-eluting stent (SES) implantation was evaluated on Major adverse cardiovascular events (MACE: composite of cardiovascular death, myocardial infarction, and target lesion revascularization) at 24 months. Inspiron sirolimus-eluting stent implantation resulted in a 24-month cumulative major cardiovascular events incidence of 6.7% and stent thrombosis rate of 0.6% in 2,803 real-world PCI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: